About Tandem Diabetes Care, Inc. - Common Stock (TNDM)
Tandem Diabetes Care is a medical device company that specializes in the development and manufacturing of innovative products for people with diabetes. The company focuses on creating advanced insulin delivery systems, including insulin pumps and related software solutions, designed to improve the management of diabetes for individuals who rely on insulin therapy. By leveraging cutting-edge technology, Tandem aims to enhance the user experience, offering features such as automated insulin delivery and seamless data integration, ultimately helping patients achieve better health outcomes and greater convenience in their daily lives. Read More
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies.
The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 3.5% in the morning session after a Citi analyst downgraded the stock. Citi analyst Joanna Wuensch downgraded Tandem Diabetes Care from a "Neutral" to a "Sell" rating and significantly cut the price target on the shares to $24 from $35. This move signals rising concerns about the company's future performance and competitive position in the diabetes technology market.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, August 6, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2025 financial and operating results.
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology now works with Abbott’s FreeStyle Libre® 3 Plus continuous glucose monitoring (CGM) sensor. The Company has initiated an early access program in the United States (U.S.), and intends to scale availability in the second half of 2025.
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin delivery systems.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with Tandem's innovative insulin delivery systems to provide more options for people to manage their diabetes.
PALM BEACH, Fla., June 17, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report, Grand View Research said that the global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion. The report said: “Diabetes is a globally prevalent health concern. It can result in Diabetic Retinopathy (DR), which is caused by damage to the blood vessels in the retina. DR leads to blurred vision and vision loss in most cases. International Diabetes Federation estimates that 1 in 8 adults will be living with diabetes in 2050. It also states urbanization, an aging population, decreasing physical activity, and the growing prevalence of obesity are some of the key aspects contributing to the rise in type 2 diabetes. DR is a serious microvascular complication of type I and type II diabetes. It is often caused by prolonged high blood sugar levels that damage the blood vessels in the retina. It can progress to sight-threatening stages, which can cause blindness and visual impairment if not treated. According to a report published by the WHO, DR is responsible for 4.8% of the 37 million blindness cases in the world. The prevalence of this condition in the U.S. is expected to increase rapidly. Despite all the necessary measures adopted by the diabetic population, DR can lead to permanent blindness based on the disease stage and severity of the condition. Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Novo Nordisk A/S (NYSE: NVO), Insulet Corporation (NASDAQ: PODD), Medtronic plc (NYSE: MDT).
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Tandem Diabetes (NASDAQ:TNDM) and its peers.
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. A poor auction for 20-year U.S. Treasury bonds further raised concerns, as weak demand implies investors are becoming more cautious about holding long-dated U.S. debt.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media following.
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) announced better-than-expected revenue in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its non-GAAP loss of $0.67 per share was 9.5% below analysts’ consensus estimates.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences:
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its GAAP loss of $1.97 per share was significantly below analysts’ consensus estimates.
